tweenvest

Shanghai Bao Pharmaceuticals Co., Ltd. (SEHK: 2659)

Salud · Biotecnología · CN

10,44 HK$

-8,42 % hoy · -83,4 % 1 año

Ficha pública
Un resumen gratuito de Shanghai Bao Pharmaceuticals Co., Ltd., con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

Shanghai Bao Pharmaceuticals Co., Ltd. (SEHK: 2659) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 430,25 M $ y tiene 354 empleados.

En los últimos doce meses la acción ha bajado un 83,4 % y ha cotizado entre 6,48 y 206,00.

Tweenvest puntúa a Shanghai Bao Pharmaceuticals Co., Ltd. en cuatro factores: calidad 54/100, valor 76/100. Su punto más fuerte es valor.

Evolución de la cotización de 2659

12 dic 2025 · 68,35Cierres semanales 7,79 – 182,3013 nov 2026 · 10,44

Cifras clave

Capitalización
430,25 M $
Ingresos (últ. 12 m)
2,51 M $
PER
-8,20
BPA
-1,38
Rent. por dividendo
—
Beta (5 años)
—
Máximo 52 semanas
206,00 HK$
Mínimo 52 semanas
6,48 HK$
Volumen medio (3 m)
—
Acciones en circulación
323,29 M
Empleados
354
Próximos resultados
—

Sobre Shanghai Bao Pharmaceuticals Co., Ltd.

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium–sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.

ISIN
CNE100007B92
Fundada en
2019
Cotiza desde
10 dic 2025
Bolsa
The Stock Exchange of Hong Kong Ltd.
Divisa
HKD
EmpresaCapitalizaciónPrecioDía
Qingdao Vland Biotech INC.SHSE: 603739440,25 M $11,60 CN¥+0,87 %
Jiangsu Sihuan Bioengineering Co., LtdSZSE: 000518435,38 M $2,82 CN¥+0,71 %
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.SEHK: 3378431,98 M $24,88 HK$-0,08 %
Kexing Biopharm Co., Ltd.SHSE: 688136430,33 M $14,45 CN¥-1,43 %
Prothena Corporation plcNasdaqGS: PRTA428,77 M $8,35 $+1,09 %
Gongwin Biopharm Holdings Co., Ltd.TPEX: 6617428,25 M $116,50 NT$-6,80 %
Ovid Therapeutics Inc.NasdaqCM: OVID426,53 M $2,26 $+1,80 %
Guanhao Biotech Co.,Ltd.SZSE: 300238425,51 M $10,34 CN¥-2,73 %

Ver todas las empresas de biotecnología →